Pfizer/Eyetech Macugen Clears FDA; Firms See Broad Medicare Coverage
Executive Summary
Pfizer/Eyetech's launch of the ophthalmic agent Macugen should be helped by a relatively generous initial reimbursement under Medicare Part B
You may also be interested in...
Lucentis Approval For Wet AMD Includes Less Frequent Dosing Option
FDA's June 30 approval of Genentech's Lucentis (ranibizumab) for the treatment of neovascular (wet) age-related macular degeneration includes the possibility for less frequent, quarterly dosing
Lucentis Approval For Wet AMD Includes Less Frequent Dosing Option
FDA's June 30 approval of Genentech's Lucentis (ranibizumab) for the treatment of neovascular (wet) age-related macular degeneration includes the possibility for less frequent, quarterly dosing
OSI Joins Genentech In Eye Disease Market With $935 Mil. Eyetech Purchase
OSI Pharmaceuticals' existing partnership with Genentech will be unaffected by the firm's acquisition of Eyetech Pharmaceuticals, CEO Colin Goddard assured investors Aug. 22